Video
Dr David Snyder on Responses to Ruxolitinib in Patients With Acute GVHD
A majority of patients with acute graft-versus-host disease (GVHD), but not all, have significant responses to the addition of ruxolitinib, said David Snyder, MD, associate chair of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
A majority of patients with acute graft-versus-host disease (GVHD), but not all, have significant responses to the addition of ruxolitinib, said David Snyder, MD, associate chair of the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
Transcript
What responses have been seen with ruxolitinib in patients with acute graft-versus-host disease?
So, it’s a majority of patients, not all unfortunately, but over 50% of patients, who have steroid-refractory GVHD will respond significantly to the addition of ruxolitinib, and that’s measured by seeing resolution of the signs and symptoms of acute GVHD, seeing that the use of corticosteroids, prednisone, methylprednisolone can be reduced or completely tapered off, and hopefully seeing that more patients will survive despite developing severe GVHD.
